A recent study presented at the 2018 Gastrointestinal Cancers Symposium identified the difference between right-sided and left-sided tumors in regard to disease-free survival outcomes in patients with late stage, high-risk colorectal cancer.
In an early session at the Clinical Pathways Congress, Bert H O’Neil, MD, Indian University Simon Cancer Center (Indianapolis, IN) discussed some of the important factors to consider when developing a clinical pathway for colorectal cancer.
Post-operative chemotherapy may be just as effective as chemoradiotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the European Society for Medical Oncology (ESMO) 18th World Congress of Gastrointestinal Cancer (June 29 – July 2, 2016; Barcelona, Spain).
The physical location of a primary tumor may be an indicator of survivor in patients with metastatic colorectal cancer (mCRC), according to results from a large retrospective study presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL (June 3-7, 2016).
A recent study examined the association between colorectal cancer messenger RNA (mRNA) expression of HER3 with response to anti-EGFR agents, published in JAMA Oncology (online October 26, 2017; doi:10.1001/jamaoncol.2017.3168).
A pooled analysis investigated the prognostic role of DNA mismatch repair (MMR) status in patients with stage III colon cancer treated with a standard adjuvant chemotherapy regimen, published in JAMA Oncology (online October 5, 2017; doi:10.1001/jamaoncol.2017.2899).
Recent research has uncovered an association between tumor origin and mortality among patients receiving systemic chemotherapy plus biologic therapy for metastatic colorectal cancer, published in JAMA Surgery (online September 20, 2017; doi:10.1001/jamasurg.2017.3466).
Short-course preoperative radiotherapy combined with delayed surgery reduces the adverse effects of rectal cancer surgery while maintaining its efficiency, according to a study published in The Lancet (published online February 9, 2017; doi: 10.1016/S1470-2045(17)30086-4).
Chemotherapy may be overused among young and middle-aged patients with colon cancer, according to a study published in JAMA Surgery (published online January 25, 2017; doi: 10.1001/jamasurg.2016.5050).
The addition of BRAF-inhibitor vemurafenib to irinotecan and cetuximab chemotherapy treatment improves progression-free survival (PFS) for patients with BRAF-mutant metastatic colorectal cancer, according to a presentation at the Gastrointestinal Cancers Symposium.
The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer, according to a presentation at the Gastrointestinal Cancers Symposium.